Turkiye Klinikleri Journal of Medical Sciences

.: ORIGINAL RESEARCH
The Evaluation of Cardiovascular Risk Parameters Using Multiplex Immunoassay in Women with Primary Hyperlipiemia and Obese HyperlipidemicWomen
Primer Hiperlipidemik ve Obez Hiperlipidemik Bayanlarda Multiplex Immunoassay Yöntemi Kullanılarak Kardiyovasküler Risk Parametrelerinin Değerlendirilmesi
Ü. Betül BACAKa, Fatma Hümeyra YERLİKAYAa, Ümmügülsüm CANb, Murat BAŞc
aDepartment of Biochemistry, Necmettin Erbakan University Meram Faculty of Medicine,
Clinics of
bBiochemistry,
cInternal Medicine, Konya Education and Research Hospital, Konya, TURKEY
Turkiye Klinikleri J Med Sci. 2019;39(3):319-27
doi: 10.5336/medsci.2018-63907
Article Language: EN
Full Text
ABSTRACT
 Objective: In order to detect the damage caused by obesity and hyperlipidemia to the cardiovascular system in the early period, parameters that will be used for follow up of these diseases and provide information about the changes are needed. It is of course valuable to measure multiple parameters simultaneously with fast, high efficiency and less sample quantity in the measurement of these parameters. Material and Methods: We have studied serum levels of cardiovascular risk parameters sE-Selectin, follistatin, PAPP-A, sPECAM-1, pentraxin-3 and tissue factor using the multiplex immunoassay method in women primary hyperlipidemic and obese hyperlipidemic. In addition, lipid profile, liver enzymes and blood glucose were measured by routine methods. We have studied these parameters in serum of 30 healthy women, 28 primary hyperlipidemic and 32 obese hyperlipidemic women. Results: sE-selectin (p<0.01) levels were significantly higher than control group. Serum follistatin levels were significantly higher in obese hyperlipidemic group (p<0.001) in obese hyperlipidemic group and primary hyperlipidemic group (p<0.01) compared to control group. Moreover serum sPECAM-1 (p<0.001) levels were significantly higher in obese hyperlipidemic group and primary hyperlipidemic group compared to control group. There were no significant differences between serum PAPP-A, pentraxin-3 and tissue factor levels of the groups. Conclusion:Our findings suggest that hyperlipidemia associated with obesity may be the cause of cardiovascular disease rather than hyperlipidemia.

Keywords: sE-Selectin; follistatin; PAPP-A; sPECAM-1; pentraxin-3; tissue factor
ÖZET
 Amaç: Obezite ve hiperlipideminin kardiyovasküler sisteme verdiği hasarın erken dönemde ortaya konabilmesi için bu hastalıkların takibinde kullanılacak ve değişiklikler hakkında bilgi verecek parametrelere gereksinim duyulmaktadır. Bu parametrelerin ölçümünde eşzamanlı olarak birden fazla parametrenin hızlı, yüksek verimli ve daha az numune miktarı ile saptanması elbette değerli olacaktır. Gereç ve Yöntemler: Bu kapsamda çalışmamızda primer hiperlipidemik ve obez hiperlipidemik kadınlarda multiplex immunoassay yöntemi kullanılarak kardiyovasküler risk parametrelerinin (sE-Selektin, follistatin, PAPP-A, sPECAM-1, pentraxin-3, doku faktörü) serum seviyeleri araştırıldı. Ayrıca, katılımcıların serumlarında lipid profili, karaciğer enzimleri ve kan glukozu rutin yöntemler ile ölçüldü. Hedeflenen parametreler 28 primer hiperlipidemik, 32 obez hiperlipidemik ve 30 sağlıklı kadında çalışıldı. Bulgular: Çalışmamızda obez hiperlipidemik gruba ait sE-Selektin düzeyleri kontrol grubuna göre önemli derecede yüksek bulunmuştur (p<0,01). Obez hiperlipidemik gruba ait serum follistatin (p<0,001) ve hiperlipidemik gruba ait serum follistatin düzeyleri (p<0,01) kontrol grubuna göre önemli derecede yüksek bulunmuştur. Bunun yanında obez hiperlipidemik ve hiperlipidemik gruba ait serum sPECAM-1 (p<0,001) düzeyleri kontrol grubuna göre önemli derecede yüksek bulunmuştur. Gruplara ait serum PAPP-A, pentraxin-3 ve doku faktörü düzeylerinde önemli bir istatistiki fark bulunamamıştır. Sonuç: Bulgularımız, obeziteyle birlikte ortaya çıkan hiperlipideminin sadece hiperlipidemi varlığından daha çok kardiyovasküler hastalıkların oluşmasında etken olabileceğini göstermektedir.

Anahtar Kelimeler: sE-Selektin, follistatin; PAPP-A; sPECAM-1; pentraxin-3; doku faktörü
REFERENCES:
  1. Cortner JA, Coates PM, Gallagher PR. Prevalence and expression of familial combined hyperlipidemia in childhood. J Pediatr. 1990; 116(4):514-9. [Crossref] 
  2. Demant T, Gaw A, Watts GF, Durrington P, Buckley B, Imrie CW, et al. Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia. J Lipid Res. 1993;34(1):147-56.
  3. Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013;5(4):1218-40. [Crossref]  [PubMed]  [PMC] 
  4. Cihangir E. [Prevalence of overweight and obesity in Turkey]. IJC Metabolic & Endocrine. 2015;8:38-41. [Crossref] 
  5. Alkan HÖ, Enç N. The role of nursing in cardiovascular disease prevention in women. Turk Soc Cardiol Turkish Journal of Cardiovascular Nursing. 2013;4(5):14-29. [Crossref] 
  6. Zhang L, Liu K, Han B, Xu Z, Gao X. The emerging role of follistatin under stresses and its implications in diseases. Gene. 2018;639:111-6. [Crossref]  [PubMed] 
  7. Dohi T, Ejima C, Kato R, Kawamura YI, Kawashima R, Mizutani N, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128(2):411-23. [Crossref]  [PubMed] 
  8. Casula M, Montecucco F, Bonaventura A, Liberale L, Vecchié A, Dallegri F, et al. Update on the role of pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1-12. [Crossref]  [PubMed] 
  9. Wodok-Wieczorek K, Salwowska N, Syguła E, Wodok A, Wcisło-Dziadecka D, Bebenek K, et al. The correlation between serum E-selectin levels and soluble interleukin-2 receptors with relation to disease activity in localized scleroderma. Postepy Dermatol Alergol. 2018;35(6):614-9. [Crossref]  [PubMed]  [PMC] 
  10. Ustündağ M, Orak M, Güloğlu C, Sayhan MB, Alyan O, Kale E. Comparative diagnostic accuracy of serum levels of neutrophil activating peptide-2 and pentraxin-3 versus troponin-I in acute coronary syndrome. Anadolu Kardiyol Derg. 2011;11(7):588-94. [Crossref]  [PubMed] 
  11. Roldán V, Marín F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost. 2003;90(6):1007-20. [Crossref]  [PubMed] 
  12. Newton JP, Hunter AP, Simmons DL, Buckley CD, Harvey DJ. CD31 (PECAM-1) exists as a dimer and is heavily N-glycosylated. Biochem Biophys Res Commun. 1999;261(2):283-91. [Crossref]  [PubMed] 
  13. Yu XH, He LH, Gao JH, Zhang DW, Zheng XL, Tang CK. Pregnancy-associated plasma protein-A in atherosclerosis: molecular marker, mechanistic insight, and therapeutic target. Atherosclerosis. 2018;278:250-8. [Crossref]  [PubMed] 
  14. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345(14):1022-9. [Crossref]  [PubMed] 
  15. Ruf W, Samad F. Tissue factor pathways linking obesity and inflammation. Hamostaseologie. 2015;35(3):279-83. [Crossref]  [PubMed]  [PMC] 
  16. Papapanagiotou A, Siasos G, Kassi E, Gargalionis AN, Papavassiliou AG. Novel Inflammatory markers in hyperlipidemia: clinical implications. Curr Med Chem. 2015;22(23): 2727-43. [Crossref]  [PubMed] 
  17. Conover CA, Harrington SC, Bale LK, Oxvig C. Surface association of pregnancy-associated plasma protein-A accounts for its colocalization with activated macrophages. Am J Physiol Heart Circ Physiol. 2007;292(2):H994-H1000. [Crossref]  [PubMed] 
  18. Cosin-Sales J, Kaski JC, Christiansen M, Kaminski P, Oxvig C, Overgaard MT, et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics, and coronary artery disease extent in patients with chronic stable angina pectoris. Eur Heart J. 2005;26(20):2093-8. [Crossref]  [PubMed] 
  19. Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, et al. Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I levation. Circulation. 2003;108(16): 1924-6. [Crossref]  [PubMed] 
  20. Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR Jr, Overgaard MT, et al. Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J. 2006;27(14):1678-84. [Crossref]  [PubMed] 
  21. Egert S, Baxheinrich A, Lee-Barkey YH, Tschoepe D, Wahrburg U, Stratmann B. Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits. Br J Nutr. 2014;112(8):1315-22. [Crossref]  [PubMed] 
  22. Szabová M, Jahnová E, Horváthová M, Ilavská S, Pružincová V, Nemessányi T, et al. Changes in immunologic parameters of humoral immunity and adipocytokines in obese persons are gender dependent. Hum Immunol. 2012;73(5):486-92. [Crossref]  [PubMed] 
  23. Ito H, Ohshima A, Inoue M, Ohto N, Nakasuqa K, Kaji Y, et al. Weight reduction decreases soluble cellular adhesion molecules in obese women. Clin Exp Pharmacol Physiol. 2002;29(5-6):399-404. [Crossref]  [PubMed] 
  24. Adamska A, Karczewska-Kupczewska M, Nikołajuk A, Otziomek E, Górska M, Kowalska I, et al. Relationships of serum soluble E-selectin concentration with insulin sensitivity and metabolic flexibility in lean and obese women. Endocrine. 2014;45(3):422-9. [Crossref]  [PubMed]  [PMC] 
  25. Blann AD, Davis A, Miller JP, McCollum CN. Von Willebrand factor and soluble E-selectin in hyperlipidemia: relationship to lipids and vascular disease. Am J Hematol. 1997;55(1):15-23. [Crossref] 
  26. Johnston TP. Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice. J Pharm Pharmacol. 2009;61(12):1681-8. [Crossref]  [PubMed] 
  27. Nomura S, Takahashi N, Inami N, Kajiura T, Yamada K, Nakamori H, et al. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis. 2004;174(2):329-35. [Crossref]  [PubMed] 
  28. Witasp A, Carrero JJ, Michaëlsson K, Ahlström H, Kullberg J, Adamsson V, et al. Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss. Obesity (Silver Spring). 2014;22(5):1373-9. [Crossref]  [PubMed] 
  29. Miyaki A, Maeda S, Choi Y, Akazawa N, Eto M, Tanaka K, et al. Association of plasma pentraxin 3 with arterial stiffness in overweight and obese individuals. Am J Hypertens. 2013;26(10):1250-5. [Crossref]  [PubMed] 
  30. Sahin FK, Sahin SB, Balik G, Ural UM, Tekin YB, Cure MC, et al. Does low pentraxin-3 levels associate with polycystic ovary syndrome and obesity. Int J Clin Exp Med. 2014;7(10):3512-9.
  31. Barazzoni R, Palmisano S, Gortan Cappellari G, Giuricin M, Moretti E, Vinci P, et al. Gastric bypass-induced weight loss alters obesity-associated patterns of plasma pentraxin-3 and systemic inflammatory markers. Surg Obes Relat Dis. 2016;12(1):23-32. [Crossref]  [PubMed] 
  32. Jylhävä J, Haarala A, Kähönen M, Lehtimäki T, Jula A, Moilanen L, et al. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol. 2011;164(2):211-7. [Crossref]  [PubMed]  [PMC] 
  33. Brandt C, Pedersen M, Rinnov A, Andreasen AS, Møller K, Hojman P, et al. Obesity and low-grade inflammation increase plasma follistatin-like 3 in humans. Mediators Inflamm. 2014;2014:364209. [Crossref]  [PubMed]  [PMC] 
  34. Fan N, Sun H, Wang Y, Wang Y, Zhang L, Xia Z, et al. Follistatin-like 1: a potential mediator of inflammation in obesity. Mediators Inflamm. 2013;2013:752519. [Crossref]  [PubMed]  [PMC] 
  35. Ay L, Thaler J, Brix JM, Schernthaner GH, Ay C, Pabinger I, et al. Decrease in microvesicle-associated tissue factor activity in morbidly obese patients after bariatric surgery. Int J Obes (Lond). 2016;40(5):768-72. [Crossref]  [PubMed] 
  36. Camerer E, Kolstø AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res. 1996;81(1):1-41. [Crossref] 
  37. Owens AP 3rd, Byrnes JR, Mackman N. Hyperlipidemia, tissue factor, coagulation, and simvastatin. Trends Cardiovasc Med. 2014;24(3):95-8. [Crossref]  [PubMed]  [PMC] 
  38. Lin HL, Yen HW, Hsieh SL, An LM, Shen KP. Low-dose aspirin ameliorated hyperlipidemia, adhesion molecule, and chemokine production induced by high-fat diet in Sprague-Dawley rats. Drug Dev Res. 2014;75(2):97-106. [Crossref]  [PubMed] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com